

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617sxx

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	4	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	5	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	6	FEB 10	COMPENDEX reloaded and enhanced
NEWS	7	FEB 11	WTEXTILES reloaded and enhanced
NEWS	8	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	9	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	10	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	11	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	12	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	13	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	14	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	15	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	16	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	17	MAR 11	ESBIOBASE reloaded and enhanced
NEWS	18	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS	19	MAR 23	CA/CAPLUS enhanced with more than 250,000 patent equivalents from China
NEWS	20	MAR 30	IMSPATENTS reloaded and enhanced
NEWS	21	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS	22	APR 07	STN is raising the limits on saved answers
NEWS	23	APR 24	CA/CAPLUS now has more comprehensive patent assignee information
NEWS	24	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS	25	APR 28	CAS patent authority coverage expanded
NEWS	26	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS	27	APR 28	Limits doubled for structure searching in CAS REGISTRY

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,

AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:27:01 ON 29 APR 2009

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'CAPLUS' ENTERED AT 15:27:28 ON 29 APR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Apr 2009 VOL 150 ISS 18

FILE LAST UPDATED: 28 Apr 2009 (20090428/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.50	0.72

FILE 'REGISTRY' ENTERED AT 15:27:32 ON 29 APR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 APR 2009 HIGHEST RN 1140067-87-3
DICTIONARY FILE UPDATES: 27 APR 2009 HIGHEST RN 1140067-87-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>


```
=> s deramciclane
L1          5 DERAMCICLANE

=> s deramciclane/cn
L2          1 DERAMCICLANE/CN

=> d L2 str cn rn
```

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
CN  Ethanamine, N,N-dimethyl-2-[[ (1R,2S,4R)-1,7,7-trimethyl-2-
    phenylbicyclo[2.2.1]hept-2-yl]oxy]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN  Ethanamine, N,N-dimethyl-2-[(1,7,7-trimethyl-2-phenylbicyclo[2.2.1]hept-2-
    yl)oxy]-, (1R-exo)-
OTHER NAMES:
CN  Deramciclane
RN  120444-71-5 REGISTRY
```

```
=> file caplus
COST IN U.S. DOLLARS          SINCE FILE          TOTAL
                                ENTRY          SESSION
FULL ESTIMATED COST          13.23          13.95
```

FILE 'CAPLUS' ENTERED AT 15:28:24 ON 29 APR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Apr 2009 VOL 150 ISS 18
FILE LAST UPDATED: 28 Apr 2009 (20090428/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s deramciclane
L3          83 DERAMCICLANE
```

```
=> s 120444-71-5
    REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.
```

```
L5          75 L4
```

```
=> s L3 or L4
          75 L4
L6          92 L3 OR L4
```

```
=> dup rem L6
PROCESSING COMPLETED FOR L6
L7          92 DUP REM L6 (0 DUPLICATES REMOVED)
```

```
=> s sclerosis or creutzfeld
    34891 SCLEROSIS
    30 SCLEROSES
    34906 SCLEROSIS
        (SCLEROSIS OR SCLEROSES)
    24 CREUTZFELD
L8          34929 SCLEROSIS OR CREUTZFELD
```

```
=> s L7 and L8
```

L9 92 S L7
L10 2 L9 AND L8

=> d 1-2 ibib abs L10

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:100738 CAPLUS
DOCUMENT NUMBER: 144:198849
TITLE: Novel dosage form comprising modified-release and immediate-release active ingredients
INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060024365	A1	20060202	US 2005-134633	20050519
IN 2002MU00697	A	20040529	IN 2002-MU697	20020805
IN 193042	A1	20040626		
IN 2002MU00699	A	20040529	IN 2002-MU699	20020805
IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
US 20040096499	A1	20040520	US 2003-630446	20030729
PRIORITY APPLN. INFO.:			IN 2002-MU697	A 20020805
			IN 2002-MU699	A 20020805
			IN 2003-MU80	A 20030122
			IN 2003-MU82	A 20030122
			US 2003-630446	A2 20030729

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1156477 CAPLUS
DOCUMENT NUMBER: 142:69207
TITLE: Use of bicyclo[2.2.1]heptane derivatives for the preparation of neuroprotective pharmaceutical compositions
INVENTOR(S): Gacsalyi, Istvan; Gigler, Gabor; Harsin, Laszlo Gabor; Levay, Gyoergy; Moricz, Krisztina; Simo, Annamaria; Szenasi, Gabor
PATENT ASSIGNEE(S): Egis Gyogyszergyar Rt., Hung.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2004112769	A1	20041229	WO 2004-HU62	20040622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
HU 2003001906	A2	20060228	HU 2003-1906	20030623
HU 2003001906	A3	20060328		
AU 2004248982	A1	20041229	AU 2004-248982	20040622
CA 2529254	A1	20041229	CA 2004-2529254	20040622
EP 1660063	A1	20060531	EP 2004-743721	20040622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1812778	A	20060802	CN 2004-80017745	20040622
BR 2004011772	A	20060808	BR 2004-11772	20040622
ZA 2005010138	A	20070328	ZA 2005-10138	20040622
JP 2007516165	T	20070621	JP 2006-516495	20040622
MX 2005014127	A	20060224	MX 2005-14127	20051221
KR 2006023997	A	20060315	KR 2005-724601	20051222
NO 2006000277	A	20060119	NO 2006-277	20060119
BG 109414	A	20061130	BG 2006-109414	20060123
US 20060258750	A1	20061116	US 2006-562393	20060425
PRIORITY APPLN. INFO.:			HU 2003-1906	A 20030623
			WO 2004-HU62	W 20040622
OTHER SOURCE(S):		MARPAT 142:69207		
GI				



AB The invention relates to the use of compds. of the general Formula I, (wherein R3 stands for hydrogen or hydroxy; R1 stands for hydrogen or alkyl; and R2 stands for alkyl) and pharmaceutically acceptable acid addition salts for the preparation of pharmaceutical compns. having neuroprotective effect.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s L6 and (AY<2004 or PY<2004 or PRY<2004)

4798118 AY<2004

24035331 PY<2004

4270650 PRY<2004

L11 73 L6 AND (AY<2004 OR PY<2004 OR PRY<2004)

=> s neuroprotection or neuroprotective

9551 NEUROPROTECTION

4 NEUROPROTECTIONS

9553 NEUROPROTECTION
(NEUROPROTECTION OR NEUROPROTECTIONS)
26009 NEUROPROTECTIVE
20 NEUROPROTECTIVES
26012 NEUROPROTECTIVE
(NEUROPROTECTIVE OR NEUROPROTECTIVES)

L12 28779 NEUROPROTECTION OR NEUROPROTECTIVE

=> s L6 and L12

L13 3 L6 AND L12

=> d 1-3 L13 ibib abs

L13 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:100738 CAPLUS

DOCUMENT NUMBER: 144:198849

TITLE: Novel dosage form comprising modified-release and immediate-release active ingredients

INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar

PATENT ASSIGNEE(S): India

SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060024365	A1	20060202	US 2005-134633	20050519
IN 2002MU00697	A	20040529	IN 2002-MU697	20020805
IN 193042	A1	20040626		
IN 2002MU00699	A	20040529	IN 2002-MU699	20020805
IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
US 20040096499	A1	20040520	US 2003-630446	20030729
PRIORITY APPLN. INFO.:			IN 2002-MU697	A 20020805
			IN 2002-MU699	A 20020805
			IN 2003-MU80	A 20030122
			IN 2003-MU82	A 20030122
			US 2003-630446	A2 20030729

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

L13 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:1156477 CAPLUS

DOCUMENT NUMBER: 142:69207


TITLE: Use of bicyclo[2.2.1]heptane derivatives for the preparation of neuroprotective pharmaceutical compositions

INVENTOR(S): Gacsalyi, Istvan; Gigler, Gabor; Harsin, Laszlo Gabor; Levay, Gyoergy; Moricz, Krisztina; Simo, Annamaria; Szenasi, Gabor

PATENT ASSIGNEE(S): Egis Gyogyszergyar Rt., Hung.

SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004112769	A1	20041229	WO 2004-HU62	20040622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
HU 2003001906	A2	20060228	HU 2003-1906	20030623
HU 2003001906	A3	20060328		
AU 2004248982	A1	20041229	AU 2004-248982	20040622
CA 2529254	A1	20041229	CA 2004-2529254	20040622
EP 1660063	A1	20060531	EP 2004-743721	20040622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1812778	A	20060802	CN 2004-80017745	20040622
BR 2004011772	A	20060808	BR 2004-11772	20040622
ZA 2005010138	A	20070328	ZA 2005-10138	20040622
JP 2007516165	T	20070621	JP 2006-516495	20040622
MX 2005014127	A	20060224	MX 2005-14127	20051221
KR 2006023997	A	20060315	KR 2005-724601	20051222
NO 2006000277	A	20060119	NO 2006-277	20060119
BG 109414	A	20061130	BG 2006-109414	20060123
US 20060258750	A1	20061116	US 2006-562393	20060425
PRIORITY APPLN. INFO.:			HU 2003-1906	A 20030623
			WO 2004-HU62	W 20040622
OTHER SOURCE(S):			MARPAT 142:69207	
GI				



AB The invention relates to the use of compds. of the general Formula I, (wherein R3 stands for hydrogen or hydroxy; R1 stands for hydrogen or alkyl; and R2 stands for alkyl) and pharmaceutically acceptable acid addition salts for the preparation of pharmaceutical compns. having neuroprotective effect.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

DOCUMENT NUMBER: 138:343854
 TITLE: Buccal sprays or capsules containing drugs for treating disorders of the central nervous system
 INVENTOR(S): Dugger, Harry A., III
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 537,118.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 19
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030077227	A1	20030424	US 2002-230060	20020829
WO 9916417	A1	19990408	WO 1997-US17899	19971001
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 1036561	A1	20000920	EP 2000-109357	19971001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1952802	A2	20080806	EP 2007-23005	19971001
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
EP 2042161	A1	20090401	EP 2008-20267	19971001
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2497262	A1	20040429	CA 2003-2497262	20030827
WO 2004035021	A2	20040429	WO 2003-US26847	20030827
WO 2004035021	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003298564	A1	20040504	AU 2003-298564	20030827
EP 1539106	A2	20050615	EP 2003-796314	20030827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006505569	T	20060216	JP 2004-545251	20030827
US 20040141923	A1	20040722	US 2003-671720	20030929
US 20040265239	A1	20041230	US 2003-671715	20030929
US 20050163719	A1	20050728	US 2003-671709	20030929
US 20040120895	A1	20040624	US 2003-726585	20031204
US 6977070	B2	20051220		
US 20050002867	A1	20050106	US 2004-834815	20040427
US 20060159624	A1	20060720	US 2006-384444	20060321
US 20060171896	A1	20060803	US 2006-391297	20060329
US 20060222597	A1	20061005	US 2006-442137	20060530
US 20060216240	A1	20060928	US 2006-443253	20060531

US 20060216241	A1	20060928	US 2006-443254	20060531
JP 2009079060	A	20090416	JP 2008-266598	20081015
PRIORITY APPLN. INFO.:			WO 1997-US17899	A2 19971001
			US 2000-537118	A2 20000329
			EP 1997-911621	A3 19971001
			JP 2000-513555	A3 19971001
			US 2002-230060	A 20020829
			WO 2003-US26847	W 20030827
			US 2003-671709	A3 20030929
			US 2003-671715	A3 20030929
			US 2003-671720	A3 20030929
			US 2004-834815	A3 20040427

AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biol. active compds. for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compns. of the invention comprise formulation A: aqueous polar solvent, active compound, and optional flavoring agent; formulation B: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation C: non-polar solvent, active compound, and optional flavoring agent; and formulation D: non-polar solvent, active compound, optional flavoring agent, and propellant. Thus, a lingual spray contained sumatriptan succinate 10-15, EtOH 10-20, propylene glycol 10-15, PEG 35-40, water 10-15, and flavors 2-3%.

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	40.92	58.09
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.10	-4.10

STN INTERNATIONAL LOGOFF AT 15:38:38 ON 29 APR 2009